
    
      This is a double-blind, randomized, placebo-controlled, parallel-group study. There are two
      groups of subjects with Major Depressive Disorder and insomnia symptoms randomized to
      treatment either with eszopicone 2mg or placebo daily at bedtime for 14 weeks beginning at
      visit 2. Also, all subjects receive open label treatment with escitalopram 10 or 20mg daily
      in the morning. Safety and efficacy is evaluated as well as rating scales and patient sleep
      diaries.
    
  